share_log

騰盛博藥-B：截至2024年1月31日之股份發行人的證券變動月報表

BRII-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024

香港交易所 ·  Feb 5 22:39
Summary by Moomoo AI
騰盛博藥生物科技有限公司於2024年2月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年1月31日的情況。報告顯示，公司的法定/註冊股本維持在1,200,000,000股，每股面值0.000005美元，總額6,000美元，本月無變動。已發行股份變動詳情中，根據不同行使價的股份期權計劃，有部分股份期權已行使或失效，導致變動。本月內因行使期權所得資金總額為43,024.29港元。此外，公司根據股份獎勵計劃授出的受限制股份單位中，有1,942,401份已失效，33,030份已註銷。本月普通股增加總額為234,470股。報告由聯席公司秘書李安康博士呈交。
騰盛博藥生物科技有限公司於2024年2月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年1月31日的情況。報告顯示，公司的法定/註冊股本維持在1,200,000,000股，每股面值0.000005美元，總額6,000美元，本月無變動。已發行股份變動詳情中，根據不同行使價的股份期權計劃，有部分股份期權已行使或失效，導致變動。本月內因行使期權所得資金總額為43,024.29港元。此外，公司根據股份獎勵計劃授出的受限制股份單位中，有1,942,401份已失效，33,030份已註銷。本月普通股增加總額為234,470股。報告由聯席公司秘書李安康博士呈交。
Teng Sheng Bo Pharmaceutical Biotechnology Co., Ltd. filed with Hong Kong Trading and Settlement Limited on 6 February 2024 with Hong Kong Trading and Settlement Limited, covering the situation as of 31 January 2024. The report showed that the company's regulated/registered share capital remained at 1,200,000,000 shares with a face value of $0.00005 per share for a total of $6,000, unchanged this month. In the details of changes in issued shares, some share options have been exercised or expired under share option plans with different exercise prices, causing the change. The total amount of capital gained from the exercise of options during the month was HK$43,024.29. In addition, 1,942,401 shares of the Company's restricted share units granted under the Share Award Scheme have expired and 33,030 have been written off. Ordinary shares increased to 234,470 shares this month. THE REPORT WAS PRESENTED BY DR LEE AN KANG, JOINT COMPANY SECRETARY.
Teng Sheng Bo Pharmaceutical Biotechnology Co., Ltd. filed with Hong Kong Trading and Settlement Limited on 6 February 2024 with Hong Kong Trading and Settlement Limited, covering the situation as of 31 January 2024. The report showed that the company's regulated/registered share capital remained at 1,200,000,000 shares with a face value of $0.00005 per share for a total of $6,000, unchanged this month. In the details of changes in issued shares, some share options have been exercised or expired under share option plans with different exercise prices, causing the change. The total amount of capital gained from the exercise of options during the month was HK$43,024.29. In addition, 1,942,401 shares of the Company's restricted share units granted under the Share Award Scheme have expired and 33,030 have been written off. Ordinary shares increased to 234,470 shares this month. THE REPORT WAS PRESENTED BY DR LEE AN KANG, JOINT COMPANY SECRETARY.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more